Skip to content

Pelthos Therapeutics Inc.

PTHS· NYSECore metricsCIK 1919246

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -16.25%
Market cap
$31.50M
3.93M shares
Filings
261
$15.40M
Q3 2026
-$7.90M
Q3 2026N/M FY25 yoy
-$9.69M
Q3 2026N/M FY25 yoy
-$26.21M
Q3 2026derivedN/M FY25 yoy
-$2.04
Q3 2026N/M FY25 yoy
$17.69M
Q3 2026+3,403.5% FY25 yoy
$31.50M
—
0.6×
—
-103.35%
—

Twelve months to Sep 30, 2026 · derived

Price

$8.0275.71%$24.99past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$16.80MFY 2025
$16.80M0FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$16,795,000reported
FY 20242024-12-31$0reported

Capital returns

Dividends and buybacks · FY2024 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$0.00$0.00—3.36M sh−45.0%—
FY2024—$75.00K$75.00K—6.10M sh+3.8%—

Segments

Revenue by Segments, FY2024 to FY2025FY2024FY2025Commercial operations · FY2025 · $16.21MResearch and Development operations · FY2025 · $589.00K
LineFY2025ShareChange
Commercial operations$16.21M96%—
Research and Development operations$589.00K3.5%—
Total$16.80M

From the 10-K filed Mar 19, 2026PTHS

Biological products, except diagnostic substances

Pelthos Therapeutics Inc. is the 56th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Pelthos Therapeutics Inc. · CIK 1919246 · Engraved from SEC EDGAR